HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Zydus Pharmaceuticals Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Zydus Pharmaceuticals Intelligence Report

Generated from 10 signals · 2 evidence sources

Type

Company Intelligence Report

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 74%

Evidence

56 items

Sources

12

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Zydus Pharmaceuticals maintains an active intelligence profile across Immunology, Corticosteroid, Not specified, Oncology, Chemotherapy. 10 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 74% across 2 tracked sources. Highest-priority development: FDA AP — LITHIUM CARBONATE (SUPPL). Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Zydus Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    FDA AP — LITHIUM CARBONATE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    FDA TA — ANDA219207

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    FDA TA — CARBIDOPA; LEODOPA (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    FDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    eCTD Submission Standards for eCTD v4.0 and Regional M1

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    eCTD Submission Standards for eCTD v3.2.2 and Regional M1

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    Innovative Science and Technology Approaches for New Drugs (ISTAND) Program Submission Process

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    FDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    FDA AP — ARGATROBAN IN 0.9% SODIUM CHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 619 with buyer quality 4 (Low Priority). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA AP — LITHIUM CARBONATE (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA TA — ANDA219207

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA TA — CARBIDOPA; LEODOPA (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • eCTD Submission Standards for eCTD v4.0 and Regional M1

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • eCTD Submission Standards for eCTD v3.2.2 and Regional M1

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Innovative Science and Technology Approaches for New Drugs (ISTAND) Program Submission Process

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ARGATROBAN IN 0.9% SODIUM CHLORIDE (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — LEVOTHYROXINE SODIUM (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SODIUM BICARBONATE (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Grants AP Status to Zydus' Leuprolide Acetate ANDA215826

    Oncology · Hormonal Therapy

  • FDA Grants AP Status for Zydus' Methylprednisolone ANDA206751

    Immunology · Corticosteroid

  • FDA Submission Update for ANDA220724 by Zydus Pharmaceuticals

    Not specified

  • FDA Grants AP Status for Zydus' Methotrexate Sodium Supplement

    Oncology · Chemotherapy

  • FDA Grants AP Status for Zydus' Perphenazine Supplement

    Psychiatry · Antipsychotic

  • FDA Grants AP Status for Zydus' Carbamazepine ANDA205571

    Neurology · Antiepileptic

  • FDA Grants AP Status for Zydus' Glyburide and Metformin Hydrochloride

    Diabetes · Combination Therapy

  • FDA Approval Status Update for Bosentan ANDA207760 by Zydus Pharmaceuticals

    Cardiology · Pulmonary Hypertension

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.